Unicharm Corporation

Unicharm Corporation has been granted 560 US utility patents between 2015 and 2025, placing Unicharm Corporation at rank #820 across all assignees tracked by PlainPatent. This portfolio spans 87 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.8 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a Foreign Corporation, Unicharm Corporation is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 56.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 149 grants, compared with 411 in the 2015–2019 window — a -64% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Unicharm Corporation's 10.8 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while a multi-domain presence across 87 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Unicharm Corporation against peers pursuing similar technology classes.